This is in an incredibly strong trend, so be careful of the entry point. Healthcare might give a little more opportunity like the IYH-N ETF or an equal weight XLV-N ETF.
We have a base. It was beat up by Hillary Clinton. The sector is in a secular bull market, however. This is a good place to get your initial allocation. We come into a seasonal period soon. There is decent value.
(A Top Pick Aug 10/16. Down 12.87%.) This has been frustrating with controversies and the possibility of a Clinton presidency. Now all of that has come off, and this has gapped higher from a depressed level. It is now testing that gap support at around $39. If it can hold that, there might actually be a play here. If you own this, continue to hold as there might be some good things happening.
Pharmaceutical stocks tend to do well between August and November. Between August 13 and November 21, it tends to gain an average of 5.5%, and has been positive 80% of the time over the past 20 years. This is the period were shipments of pharmaceuticals and medicines tend to increase for the start of the cold and flu season. The 3rd quarter tends to be the best quarter for some of these Pharma stocks. This ETF owns a wide variety of pharmaceutical stocks and not all of them are high yielding, but you tend to benefit from the seasonal strength. Dividend yield of about 0.5%.
Which stocks for RESP and University in 8 years? He would use healthcares such as SPDR Health Care (XLV-N) or SPDR Pharma (XPH-N). These are in a secular bull market. You could also use Van Eck Vectors Biotech (BBH-Q). This gives you a little bit of mix of all 3 sectors. He would suggest 40% and 40% on the first 2 and maybe 20% in the Biotechs.
(A Top Pick Aug 22/13. Up 14.37%.) Probably the only play that has seasonal strength through to the end of the year. Pharmaceutical stocks tend to peak right around now.
Pharmaceuticals tend to do well from right about now through to the end of the year. He had read where Obama care would be injecting $10 billion-$35 billion in additional profits into the pharmaceutical industry over the next 10 years.
SPDR Pharma ETF is a American stock, trading under the symbol XPH-N on the NYSE Arca (XPH). It is usually referred to as AMEX:XPH or XPH-N
In the last year, there was no coverage of SPDR Pharma ETF published on Stockchase.
SPDR Pharma ETF was recommended as a Top Pick by on . Read the latest stock experts ratings for SPDR Pharma ETF.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of SPDR Pharma ETF published on Stockchase.
On 2024-11-15, SPDR Pharma ETF (XPH-N) stock closed at a price of $45.12.
Lots of rhetoric around pharma around election time, but not a lot gets changed. An equal weight ETF. Hasn't done well. Prefers Vanguard's VHT in the US, cheaper and a market weighted strategy with Pfizer, Merck, and Abbott Labs.